TCM
RARE icon

Tygh Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Tygh Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-30,152
Closed -$2.88M – 101
2021
Q2 		$2.88M Sell
30,152
-316
-1% -$32.9K 0.39% 81
2021
Q1 		$3.47M Buy
30,468
+1,193
+4% +$162K 0.49% 74
2020
Q4 		$4.05M Sell
29,275
-48
-0.2% -$5.69K 0.63% 70
2020
Q3 		$2.41M Buy
+29,323
New +$2.43M 0.46% 75

Other funds holding RARE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Tygh Capital Management's RARE Position: Q3 2021 in Review

Tygh Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2021, closing a stake of 30,152 shares — an estimated $2.88M sold.

Tygh Capital Management first reported a position in RARE in Q3 2020 and held it in 4 quarters. The position peaked at $4.05M in Q4 2020. 221 funds tracked by Wall St. Rank hold RARE as of Q3 2021.

  • Tygh Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q3 2021 after selling out during the quarter.
  • Tygh Capital Management sold 30,152 Ultragenyx Pharmaceutical shares in Q3 2021, an estimated $2.88M.
  • Tygh Capital Management first reported a position in Ultragenyx Pharmaceutical in Q3 2020 and held it in 4 quarters.
  • Tygh Capital Management's Ultragenyx Pharmaceutical position peaked at $4.05M in Q4 2020.
  • 221 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2021.

Based on Tygh Capital Management's 13F filing for Q3 2021, filed 2 Nov 2021.